BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belmontes B, Sawant DV, Zhong W, Tan H, Kaul A, Aeffner F, O'Brien SA, Chun M, Noubade R, Eng J, Ma H, Muenz M, Li P, Alba BM, Thomas M, Cook K, Wang X, DeVoss J, Egen JG, Nolan-Stevaux O. Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell-cold solid tumors. Sci Transl Med 2021;13:eabd1524. [PMID: 34433637 DOI: 10.1126/scitranslmed.abd1524] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Avanzino BC, Prabhakar K, Dalvi P, Hartstein S, Kehm H, Balasubramani A, Boudreau AA, Buelow B, Chang K, Davison LM, Iyer S, Kalwit V, Lewis Wilson K, Malik-chaudhry HK, Pierson W, Pineda G, Rangaswamy US, Saiganesh S, Schellenberger U, Ugamraj HS, Yabut RD, Buelow R, Chapman J, Trinklein ND, Harris KE. A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer. OncoImmunology 2022;11:2113697. [DOI: 10.1080/2162402x.2022.2113697] [Reference Citation Analysis]
2 Chen Z, Yue Z, Yang K, Li S. Nanomaterials: small particles show huge possibilities for cancer immunotherapy. J Nanobiotechnol 2022;20:484. [DOI: 10.1186/s12951-022-01692-3] [Reference Citation Analysis]
3 Wei M, Zuo S, Chen Z, Qian P, Zhang Y, Kong L, Gao H, Wei J, Dong J. Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1017574] [Reference Citation Analysis]
4 Kirchhammer N, Trefny MP, Auf der Maur P, Läubli H, Zippelius A. Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment. Sci Transl Med 2022;14. [DOI: 10.1126/scitranslmed.abo3605] [Reference Citation Analysis]
5 Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, Lee E, Huang BZ, Huh M, Pikor L, He X, Marius R, Austin B, Duong J, Pelin A, Neault S, Azad T, Breitbach CJ, Stojdl DF, Burgess MF, Mccomb S, Auer R, Diallo J, Ilkow CS, Bell JC. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1029269] [Reference Citation Analysis]
6 Long M, Mims AS, Li Z. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. Immunol Invest 2022;:1-39. [PMID: 36259611 DOI: 10.1080/08820139.2022.2131569] [Reference Citation Analysis]
7 Glud EN, Rasmussen M, Zhang Y, Mandrup OA, Salachan PV, Borre M, Sørensen KD, Howard KA. Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design. Br J Cancer 2022. [PMID: 36243890 DOI: 10.1038/s41416-022-01994-1] [Reference Citation Analysis]
8 Zhang J, Guo Q, Wang Q, Duan Y. CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs. MedComm – Biomaterials and Applications 2022;1. [DOI: 10.1002/mba2.20] [Reference Citation Analysis]
9 Baeuerle PA, Wesche H. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities. Curr Opin Oncol 2022. [PMID: 35880455 DOI: 10.1097/CCO.0000000000000869] [Reference Citation Analysis]
10 Carter PJ, Rajpal A. Designing antibodies as therapeutics. Cell 2022;185:2789-805. [PMID: 35868279 DOI: 10.1016/j.cell.2022.05.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Poon-Andersen C, Dhoolypala H, Wong D, Soto M, Salimi-Moosavi H, Chan B, Kielczewska A, Cook KD. Development of an immunoassay for aglycosylated murine IgG1 in mouse serum via generation of a specific tool antibody. Bioanalysis 2022. [PMID: 35548877 DOI: 10.4155/bio-2022-0037] [Reference Citation Analysis]
12 Arvedson T, Bailis JM, Britten CD, Klinger M, Nagorsen D, Coxon A, Egen JG, Martin F. Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy. Annu Rev Cancer Biol 2022;6:17-34. [DOI: 10.1146/annurev-cancerbio-070620-104325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Shen Y, Eng JS, Fajardo F, Liang L, Li C, Collins P, Tedesco D, Nolan-Stevaux O. Cancer cell-intrinsic resistance to BiTE therapy is mediated by loss of CD58 costimulation and modulation of the extrinsic apoptotic pathway. J Immunother Cancer 2022;10:e004348. [PMID: 35296559 DOI: 10.1136/jitc-2021-004348] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zorn JA, Wheeler ML, Barnes RM, Kaberna J, Morishige W, Harris M, Huang RY, Lohre J, Chang YC, Chau B, Powers K, Schindler I, Neradugomma N, Thomas W, Liao X, Zhou Y, West SM, Wang F, Kotapati S, Chen G, Yamazoe S, Kosenko A, Dollinger G, Sproul T, Rajpal A, Strop P. Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model. Sci Rep 2022;12:3530. [PMID: 35241687 DOI: 10.1038/s41598-022-06953-7] [Reference Citation Analysis]
15 von Amsberg G, Alsdorf W, Karagiannis P, Coym A, Kaune M, Werner S, Graefen M, Bokemeyer C, Merkens L, Dyshlovoy SA. Immunotherapy in Advanced Prostate Cancer-Light at the End of the Tunnel? Int J Mol Sci 2022;23:2569. [PMID: 35269712 DOI: 10.3390/ijms23052569] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Cox JR, Blazeck J. Protein engineering: a driving force toward synthetic immunology. Trends Biotechnol 2021:S0167-7799(21)00208-0. [PMID: 34627648 DOI: 10.1016/j.tibtech.2021.09.005] [Reference Citation Analysis]